

International comparisons

- 336 worldwide view of the incidence of ESRD
- 338 incidence
- 339 ESRD due to diabetes
- 340 prevalence
- 341 dialysis
- 342 transplanta
- 344 summary

his international chapter provides world-wide information on end-stage renal disease. This year, we report data from 42 regions and countries which have graciously sent data to the USRDS. Such information not only allows for international comparisons, but provides a context for data on the multiple ethnic and racial groups which constitute the diverse population of the U.S. The USRDS is well aware of the considerable challenges each country faces in gathering its data, and sincerely thanks the registries and providers for their efforts.

NAVIGATION. Fig 3 Sailing

Reported rates of incident ESRD across the globe show important trends; rates have slowed in some countries, while rising or remaining stable in others. Jalisco (Mexico), the U.S., and Japan continue to have some of the highest rates, at 527, 362, and 295 per million population in 2011.

In Japan, the prevalence of ESRD reached 2,309 per million in 2011, while rates of 1,924, 1662, and 1,661 were reported in the U.S., Portugal, and Singapore.

Three in five new ESRD patients in Singapore, Jalisco (Mexico), and Malaysia are reported to have diabetes. In Malaysia, Taiwan (2010), and Singapore, rates of diabetes in patients age 65–74 were 868, 771, and 763 per million population, respectively, in 2011, while the rate for U.S. patients of this age was 584.

Hemodialysis continues to be the most common mode of therapy worldwide, evidenced by data showing that, in over 76 percent of reporting countries, at least 80 percent of patients are on this mode of therapy. In Hong Kong and Jalisco (Mexico), in contrast, peritoneal dialysis is used by 74, and 49 percent of patients, respectively. And home dialysis therapy is provided to 18.2 and 8.8 percent of patients in New Zealand and Australia.

Renal transplant rates are many times a reflection of a country's healthcare system, its infrastruture, and its cultural beliefs. As an example, transplant rates are less than 10 per million population (pmp) in Bangladesh, the Philippines, Malaysia, Boznia/Herzegovina, Thailand, Russia, Romania, and Hong Kong, but above 60 ppm in Norway and Jalisco (Mexico), and above 50 ppm in Portugal, the Netherlands, Spain, Iceland, and the U.S. Prevalent rates of functioning grafts reach 610 and 629 per million population in Portugal and Norway, but are less than 50 in Russia, Boznia/ Herzegovina, and Romania.

We invite all renal registries to participate in our international data collection, and wish to thank all currently participating registries for their willingness to provide data on their ESRD programs, giving us a worldwide perspective on patients with ESRD. • Figure 12.1; see page 447 for analytical methods. All rates are unadjusted. Data from Japan are dialysis only.



volume two


INTERNATIONAL COMPARISONS


A map such as that one is worth many hundreds, and as luck will have it, thousands of dollars. But more than this, it is a remembrance of that time before our planet was so small. When this map was made, I thought, you could live without knowing where you were not living.

Jonathan Jafran For Everything is Illuminated

vol 2 12.1


# Comparison of unadjusted ESRD incidence & prevalence worldwide





page 335





### incidence of end-stage renal disease



Data presented only for countries from which relevant information was available;" signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). Data for Belgium do not include patients younger than 20. \*Latest data for Taiwan are from 2010. Incident data for Croatia start at day 91, in 2011. Data for France include 15 regions in 2006, 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011.

Incidence of ESRD, by year 12.a (per million population)

vol 2

		2006	2007	2008	2009	2010	2011
	Argentina	141	151	144	153	154	156
	Australia	118	113	119	111	105	110
	Austria	160	154	150	150	139	137
	Bangladesh	8	13	13	13	20	32
	Belgium, Dutch speaking**	192	190	193	207	196	182
2	Belgium, French speaking**	187	187	192	199	193	188
	Bosnia/Herzegovina	133	151	149	143	133	121
	Brazil	185	140	148	99	150	176
	Canada	166	168	166	169	169	161
	Chile	141	144	153	153	156	197
	Colombia	126	146	107	103	123	93
	Croatia	142	153	153	156	142	119
	Czech Republic	186	185	182	181	198	172
1000	Denmark	119	147	126	133	120	111
	Finland	87	94	95	84	84	85
	France	144	141	148	151	151	149
8	Greece	198	192	201	205	191	203
	Hong Kong	149	147	148	132	146	157
	Iceland	69	84	72	88	107	103
	Israel	192	193	189	193	186	188
(CON)	Jalisco (Mexico)	346	372	400	419	404	527
	Japan	275	285	288	287	288	295
No.	Rep. of Korea	185	184	182	176	181	205
040	Malaysia	138	150	168	177	187	209
	Netherlands	113	117	121	119	117	117
1000	New Zealand	119	111	116	135	117	108
	Norway	100	113	113	116	104	102
	Philippines	75	87	87	91	97	103
Contraction of the	Portugal			232	240	239	226
1	Romania	75	90	97	109	124	127
	Russia	28	•	35	35	40	43
	Scotland	116	114	106	106	100	97
	Serbia				•		144
	Singapore	241	268	251	231	245	279
	Spain	128	121	128	129	121	121
	Sweden	130	128	123	127	121	122
Ì	Taiwan*	418	424	421	367	361	
1000	Thailand	139	159	100	123	146	227
	Turkey	192	229	261	257	252	238
1	U.K., England, Wales & N Ireland	115	112	113	113	109	113
8	United States	366	363	364	373	371	362
	Uruguay	138	143	166	135	153	177
1				5.52			

Incident rates of reported ESRD in 2011 were 527 per million population in Jalisco (Mexico), followed by reported rates from the United States, Taiwan (2010), and Japan at 362, 361, and 295, respectively. Rates of less than 100 per million were reported in Scotland, Colombia, Finland, Russia, & Bangladesh. As stated in previous ADRS, it is important to note the distinction between the incidence of treatment guided by available funding, and the incidence of the disease itself. An affluent nation may allow elderly patients and those with diabetes to receive hemodialysis, for example, while developing nations may restrict treatment to younger, healthier patients. + Figure 12.3 & Table 12.a; see page 447 for analytical methods. All rates are unadjusted.




volume two M



INTERNATIONAL COMPARISONS incidence of estd; estd due lo diabeles

#### end-stage renal disease due to diabetes



In 2011, diabetes was the primary cause of ESRD in 59–61 percent of new patients in Malaysia, Jalisco (Mexico), & Singapore. Israel, the Republic of Korea, Hong Kong, Taiwan (2010), the Philippines, Japan, the United States, and New Zealand all reported rates of ESRD incidence due to diabetes above 40 percent. Countries reporting rates below 20 percent included Russia, the Netherlands, Norway, and Romania.

Incident rates of ESRD due to diabetes rise with increasing age. In 2011, Malaysia, Taiwan (2010), Singapore, and the United States reported respective rates of 868, 771, 763, and 584 per million population, in patients age 65–74; rates for patients in Singapore, Taiwan, and the United States age 75 and older, were 757, 683, and 521 per million, respectively, and in the United States, rates for patients age 20–44 and 45–64 were 44 and 266 per million. **+ Figures 12.4–5;** see page 447 for analytical methods. *All rates are unadjusted*.

Data presented only for countries from which relevant information was available. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). \*Latest data for Taiwan are from 2010. ^^ Czech Republic: Data on incident ESRD due to diabetes is an estimate. Data for France include 13 regions in 2005, 15 regions in 2006, 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011. prevalence of end-stage renal disease

vol 2

12.b

Prevalence of ESRD, by year

(per million population)



Data presented only for countries from which relevant information was available; "." signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). \*\*Data for Belgium do not include patients younger than 20. Argentina (2005–2007), Bangladesh, Brazil (2005–2010), Czech Republic (2005–2008), Japan, Philippines, & Taiwan are dialysis only. \*Latest data for Taiwan are from 2010. Data for France include 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011.

	(per minor	i populati	011)								
		Prevale	nt counts				Prevale	nt rates			
		2007	2008	2009	2010	2011	2007	2008	2009	2010	2011
	Argentina	24,218	30,035	30,580	31,885	31,975	615	756	762	795	797
	Australia	16,842	17,822	18,505	19,199	19,933	801	834	850	870	893
	Austria	7,731	7,898	8,187	8,321	8,436	934	948	980	992	1,001
	Bangladesh	15,089	16,963	21,067	24,618	28,729	101	113	137	158	192
	Belgium, Dutch sp.**	6,531	6,779	7,082	7,295	7,496	1,064	1,096	1,137	1,162	1,184
	Belgium, French sp.**	4,983	5,184	5,437	5,695	5,929	1,111	1,146	1,191	1,234	1,271
	Bosnia/Herzegovina	2,306	2,441	2,477	2,587	2,473	602	637	646	675	705
	Brazil	87,044	77,589	92,091	91,314	132,491	466	415	481	479	679
	Canada	35,274	36,565	38,069	39,184	40,408	1,071	1,097	1,128	1,148	1,172
	Chile	16,360	17,856	18,849	19,854	21,007	986	1,065	1,109	1,161	1,236
	Colombia		20,239	19,846	24,760	24,692		455	441	544	536
	Croatia	3,932	4,009	4,124	4,257	4,348	886	904	930	959	980
	Czech Republic	5,190	5,633	9,536	10,218	10,236	500	538	908	970	974
	Denmark	4,592	4,619	4,706	4,745	4,786	832	832	843	847	851
	Finland	3,953	4,087	4,172	4,258	4,325	747	769	781	794	803
	France	49,679	54,627	58,810	67,018	70,322	954	993	1,026	1,056	1,091
	Greece	11,343	11,674	12,047	12,230	12,465	1,013	1,039	1,068	1,082	1,103
	Hong Kong	7,171	7,460	7,580	7,857	8,197	1,031	1,067	1,078	1,106	1,152
8	Iceland	161	166	172	190	212	518	523	540	597	665
	Israel	7,472	7,826	8,134	8,400	8,699	1,041	1,071	1,087	1,102	1,120
	Jalisco (Mexico)	6,865	7,218	9,222	9,916	10,421	986	1,030	1,314	1,332	1,382
	Japan	262,968	271,471	281,212	289,415	295,706	2,058	2,126	2,205	2,260	2,309
	Rep. of Korea	48,675	51,989	56,396	58,860	63,341	973	1,032	1,114	1,144	1,225
	Malaysia	18,825	21,139	23,346	25,473	27,983	692	768	837	902	980
	Netherlands	13,146	13,932	14,737	15,394	16,049	802	847	892	926	961
	New Zealand	3,354	3,456	3,684	3,826	3,869	793	810	863	896	906
	Norway	3,692	3,895	4,075	4,200	4,329	784	817	844	859	874
	Philippines	7,967	10,552	11,172	13,275	16,230	85	110	114	133	159
	Portugal		14,965	16,011	16,788	17,553		1,407	1,505	1,590	1,662
	Romania	7,935	9,088	10,813	12,087	13,346	368	422	503	564	624
2	Russia		22,234	24,246	26,327	27,989		157	173	186	196
	Scotland	4,177	4,186	4,296	4,371	4,421	812	810	827	837	842
	Serbia					5,275					727
	Singapore	5,165	5,443	5,699	5,952	6,295	1,442	1,494	1,526	1,578	1,661
	Spain	41,546	44,067	39,708	47,632	50,614	956	995	1,034	1,046	1,075
4	Sweden	7,929	8,074	8,294	8,541	8,787	867	876	892	911	930
	Taiwan*	52,462	54,101	56,671	59,856		2,285	2,348	2,451	2,584	
	Thailand	26,457	31,496	35,110	40,845	47,987	420	497	553	639	750
	Turkey	50,221	53,859	59,443	62,471	64,877	711	753	819	847	868
	UK^	41,188	43,633	45,698	47,493	49,682	738	776	807	833	871
	United States	516,812	537,806	560,364	582,555	601,801	1,708	1,761	1,819	1,876	1,924
	Uruguay	3,204	3,389	3,407	3,468	3,532	964	1,016	1,019	1,033	1,075

Taiwan (2010) and Japan (2011) continued to report the highest rates of prevalent ESRD, at 2,584 and 2,309 per million population, respectively. The next highest rates in 2011 were reported by the United States, at 1,924, followed by Portugal, Singapore, and Jalisco (Mexico) at 1,662, 1,661, and 1,382. The lowest rates were reported by the Philippines, Bangladesh, and Russia, at 159, 192, and 196 per million. + Figure 12.6 & Table 12.b; see page 447 for analytical methods. *All rates are unadjusted*.



volume tyvo



INTERNATIONAL COMPARISONS prevalence of estd; dialysis

# patient distribution by type of dialysis



Data presented only for countries from which relevant information was available;". signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). \*\*Data for Belgium do not include patients younger than 20. \*Latest data for Taiwan are from 2010. Data for France include 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011.

vol 2 <b>12.C</b> Percent dis dialysis pat					ar										
	Hemo	dialys	is			Hom	e hem	odialv	sis		Perito	neal d	lialysis		
		2008		2010	2011					2011			2009		2011
Argentina	96.1	96.0	96.0	95.8	95.1	0.0	0.0	0.0	0.0	0.0	3.9	4.0	4.0	4.2	4.9
Australia	68.3	68.6	69.6			9.8	9.4	9.3	9.1	8.8	22.0	22.1	21.1	19.5	18.8
Austria	91.2	91.0	91.0		91.5	0.1	0.1	0.0	0.0	0.1	8.7	8.9	8.9	8.9	8.4
Bangladesh	98.4	98.3	98.3	98.3	98.3	0.0	0.0	0.0	0.0	0.0	1.6	1.7	1.7	1.7	1.7
Belgium, Dutch sp.**	89.2	89.7	89.8	90.6	90.9	0.2	0.3	0.3	0.3	0.1	10.6	10.1	9.9	9.2	9.0
Belgium, French sp.**	90.5	90.7		89.9	90.0	1.2	1.3	1.2	1.4	1.6	8.3	8.0	8.6	8.7	8.3
Bosnia/Herzegovina	95.2	95.1	94.9	95.2	96.0	0.1	0.0	0.0	0.0	0.0	4.7	4.9	5.0	4.8	4.0
Brazil	89.4	89.6	92.3	90.6	91.6	0.0	0.0	0.0	0.0	0.0	10.6	10.4	7.7	9.4	8.4
Canada	78.6	78.3	78.4		79.0	3.0	3.3	3.5	3.7	3.9	18.4	18.4	18.1	17.8	17.1
Chile	95.2		95.3		94.6	0.0	0.0	0.0	0.0	0.0	4.8	4.7	4.7	4.9	5.4
Colombia	63.4		68.2			0.0	0.0	0.0	0.0	0.0	36.6	32.0	31.8	31.3	30.9
Croatia	92.8	91.8	91.0	91.5	92.1	0.0	0.0	0.0	0.0	0.0	7.2	8.2	9.0	8.5	7.9
Czech Republic	92.3	91.8	92.0	92.1	91.7	0.0	0.0	0.0	0.0	0.0	7.7	8.2	8.0	7.9	8.3
Denmark	71.8	-	73.7	-		3.7	4.2	4.5	4.7	4.7	24.5	22.9	21.8	21.2	20.0
Finland	75.8	74.3	75.0	77.1	77.3	3.8	3.9	3.7	3.9	4.2	20.4	21.7	21.3	18.9	18.6
France	87.4		88.5	88.5	88.9	1.6	1.3	1.2	1.0	0.9	11.1	10.8	10.3	10.5	10.2
Greece	91.7	91.7	92.0		-	0.0	0.0	0.0	0.0	0.0	8.3	8.3	7.9	7.7	7.2
Hong Kong	19.8	20.4	21.5		24.4	0.0	0.4	0.6	0.9	1.5	-	79.2			74.1
Iceland	72.1	76.6	87.1			1.6	1.6	0.0	0.0	0.0	26.2	21.9	12.9	16.7	19.8
Israel	92.9	93.6	93.3			0.0	0.0	0.0	0.0	0.0	7.1	6.4	6.7	6.2	5.9
Jalisco (Mexico)	34.2		41.5			0.0	0.0	0.0	0.0	0.0	65.8	59.6		51.3	49.4
Japan	96.7	96.8	96.7		96.8	0.0	0.0	0.0	0.0	0.0	3.3	3.1	3.2	3.2	3.1
Rep. of Korea		81.0			84.7	0.0	0.0	0.0	0.0	0.0	19.8	19.0	16.9	-	15.3
Malaysia	89.9	90.0	90.3	90.6	90.7	1.0	1.0	1.0	1.0	1.0	9.1	9.1	8.7	8.4	8.3
Netherlands	76.0	77.4		-	81.5	2.3	2.5	2.5	2.7	2.7	21.7	20.1	18.5	17.9	15.8
New Zealand	48.2	48.1	48.4	47.3	48.6	15.8	15.7	16.6	17.8	18.2	36.0	36.2	35.0	34.9	33.2
Norway	80.6		80.7			0.3	0.3	0.5	0.7	0.6	19.1	16.4	18.8	18.0	15.3
Philippines	87.3		95.6	-		0.0	0.0	0.5	0.0	0.0	12.7	6.7	4.4	4.1	3.6
Portugal	07.5	93.3	95.0			0.0	0.0	0.0	0.0	0.0	12./	5.2	4.4 5.6	6.1	5.0 6.3
Romania	81.8	82.8	84.5		87.7	0.0	0.0	0.0	0.0	0.1	18.2	17.1	15.5	13.5	12.2
Russia	01.0	91.0	91.3		91.6	0.0	0.0	0.0	0.0	0.0	10.2	9.0	8.7	8.6	8.4
Scotland	80.7	-	83.8		-	1.9	2.2	2.5	2.4	2.6	17.5	15.1	13.7	13.0	12.2
Serbia	00.7	02.0	03.0	04.0	90.1	1.9	2.2	2.5	2.4	0.7	17.5	15.1	13./	13.0	9.1
Singapore	82.5	85.6	86.3	87.4		0.1	0.1	0.1	0.1	0.1	17.4	14.4	13.6	12.5	12.8
Spain	89.4	90.6	90.6	89.8	89.3	0.1	0.3	0.1	0.1	0.1	10.5	9.2	9.2	10.0	12.0
Sweden	73.0	73.3	73.7	-	75.8	2.9	2.8	2.7	2.7	3.0	24.2	23.9	23.6	22.5	21.2
Taiwan*	91.5	90.8	/3./	74.0 89.6	/ 5.0	0.0	0.0	0.0	0.0	3.0	8.5	23.9	10.3	10.4	21.2
Thailand	91.5	-	84.1	-	78.6	0.0	0.0	0.0	0.0	0.0	0.5 5.5	9.2 9.5	15.9	18.1	21.4
Turkey	94.5 88.1	90.5 87.4		90.4	/8.0 91.8	0.0		0.0			5.5 11.9	9.5 12.5	10.4	9.6	8.2
UK^	78.9	81.0	89.0	90.4 82.0	-	2.0	0.0 2.1	2.5	0.0 2.9	0.0 3.4	19.1	12.5	15.6	9.0 15.1	8.2 14.6
United States	/8.9 92.2		92.1	91.8	91.3	0.7	0.9	2.5	2.9	3.4 1.3	7.1	6.9	6.9	7.0	
Uruquay	-	92.2 91.1	-	-		0.7	0.9	0.0	0.0	0.0	9.4	8.9	0.9 9.2	7.0 9.9	7.4 9.9
oruguay	90.0	91.1	90.0	90.1	90.1	0.0	0.0	0.0	0.0	0.0	9.4	0.9	9.2	9.9	9.9

In Hong Kong, 74 percent of prevalent dialysis patients were treated with CAPD/CCPD in 2011. Nearly half of prevalent dialysis patients in Jalisco (Mexico) use this therapy, as do 33 percent of those treated in New Zealand. In-center hemodialysis remains the most common mode of therapy worldwide; in New Zealand and Australia, however, 18.2 and 8.8 percent of patients, respectively, use home hemodialysis. + Figure 12.7 & Table 12.c; see page 447 for analytical methods.



Data presented only for countries from which relevant information was available; "." signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). \*\*Data for Belgium do not include patients younger than 20. Data for France include 15 regions in 2006, 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011.

#### vol 2 12.d

Prevalent rates of functioning grafts, by year (per million population)

	2006	2007	2008	2009	2010	2011	
Argentina			132	128	147	135	
Australia	331	338	358	370	386	400	
Austria	439	456	460	475	485	500	
Belgium, Dutch sp.**	423	439	452	464	475	495	
Belgium, French sp.**	434	453	471	487	508	531	
Bosnia/Herzegovina	32	32	40	44	42	46	
Canada	409	428	445	461	476	490	
Chile	165	175	189	191	191	210	
Colombia			61	60	89	88	
Croatia	188	205	231	261	296	336	
Czech Republic				359	370	390	
Denmark	318	334	342	360	380	399	
Finland	434	445	449	459	468	474	
France	409	407	426	446	466	483	
Greece	192	202	215	217	214	221	
Hong Kong	410	420	443	460	467	475	
Iceland	316	319	321	345	371	411	
Israel	358	372	386	383	381	392	
Jalisco (Mexico)	352	399	436	458	460	500	
Rep. of Korea	196	202	213	225	234	252	
Malaysia	66	65	65	66	66	66	
Netherlands	419	446	478	507	542	577	
New Zealand	298	303	316	325	330	338	
Norway	537	552	573	592	609	629	
Portugal			484	545	566	610	
Romania	20	22	29	34	40	47	
Russia	29	•	34	38	41	42	
Scotland	369	386	395	408	418	431	
Serbia		•	•			102	
Singapore	330	341	348	353	360	369	
Spain	445	453	505	495	516	538	
Sweden	454	469	487	499	507	520	
Thailand	20	57	36	46	50	56	
Turkey	58	80	109	102	104	95	
U.K., England, Wales & N Ireland	288	346	370	389	408	434	
United States	507	526	544	562	579	596	
Uruguay	210	235	256	273	284	313	

Reported prevalent rates of functioning grafts in 2011 were greatest in Norway, and Portugal, at 629 and 610, respectively. Countries and regions reporting rates at or above 500 per million include the United States, the Netherlands, Spain, French-speaking Belgium, Sweden, Jalisco (Mexico), and Austria. Russia, Bosnia/Herzegovina, Romania, Thailand, Malaysia, Colombia, and Turkey reported rates below 100 per million population in 2011. + Figure 12.8 & Table 12.d; see page 447 for analytical methods. All rates are unadjusted.



volume two



# transplant rates



Data presented only for countries from which relevant information was available;"." signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). \*\*Data for Belgium do not include patients younger than 20. Data for France include 15 regions in 2006, 18 regions in 2007, 20 regions in 2008 & 2009, 23 regions in 2010, & 25 regions in 2011.

vol 2 I 2.eTransplant rates, by ye (per million population						
	2006	2007	2008	2009	2010	2011
Argentina	21.7	23.0	25.1	26.4	28.4	29.1
Australia	31.0	29.3	38.0	35.5	38.3	37.0
Austria	47.9	43.7	39.5	47.4	44.6	44.6
Bangladesh	0.2	0.5	0.5	0.6	0.6	0.8
Belgium, Dutch speaking**	39.7	43.3	40.3	39.3	37.9	40.0
Belgium, French speaking**	39.3	40.8	37.4	37.7	38.8	44.6
Bosnia & Herzegovina	6.8	8.4	9.1	7.0	6.0	6.3
Brazil	17.8	18.5	20.2	22.2	24.3	25.4
Canada	38.4	39.5	38.3	37.7	37.9	37.6
Chile	18.5	17.1	16.8	15.1	13.5	15.6
Colombia	14.9	14.8	16.1	18.9	19.5	17.6
Czech Republic	41.6	38.0	31.9	34.0	27.2	31.6
Denmark	30.8	30.3	34.8	40.3	40.9	38.9
Finland	39.7	32.3	28.0	32.8	32.4	32.7
France	39.9	45.1	44.9	43.6	44.6	44.7
Greece	22.2	21.9	24.0	14.9	11.1	17.8
Hong Kong	9.6	9.5	11.0	13.4	11.3	9.3
Iceland	26.3	22.5	25.2	31.4	34.6	53.3
Israel	43.2	37.7	33.1	28.6	23.7	36.7
Jalisco (Mexico)	52.2	59.3	54.3	58.1	60.1	62.2
Rep. of Korea	18.8	18.5	22.7	24.5	25.1	31.7
Malaysia	11.1	8.2	4.7	5.1	4.5	4.3
Netherlands	41.0	51.0	47.0	49.9	52.1	51.6
New Zealand	21.5	29.1	28.6	28.0	25.2	26.8
Norway	45.5	55.2	58.3	60.5	53.8	61.0
Philippines	7.5	11.1	7.1	5.2	4.0	3.8
Portugal			49.4	55.7	54.3	50.2
Romania	5.3	2.8	7.3	6.3	6.1	8.1
Russia	2.9		5.5	5.9	7.3	6.8
Scotland	26.4	37.7	41.0	40.8	35.2	37.3
Serbia						15.6
Singapore	24.1	23.2	20.0	18.5	16.2	17.7
Spain	48.2	47.3	48.3	49.8	47.3	52.9
Sweden	40.5	42.3	45.6	42.3	39.3	45.2
Thailand	3.6	5.9	5.4	4.8	5.5	6.3
Turkey	11.6	18.6	18.1	26.3	34.5	39.3
U.K., England, Wales & N Ireland	34.1	38.3	40.5	42.5	44.5	43.9
United States	60.6	58.3	57.2	57.8	57.4	56.6
Uruguay	42.8	28.9	37.5	35.0	25.6	39.0

In 2011, Jalisco (Mexico), Norway, the United States, Iceland, Spain, the Netherlands, and Portugal, reported transplant rates above 50 per million population, at 62, 61, 57, 53, 53, 52, and 51, respectively. Rates were less than 10 per million, in contrast, in Hong Kong, Romania, Russia, Thailand, Boznia/Herzegovina, Malaysia, the Philippines, and Bangladesh. + Figure 12.9 & Table 12.e; see page 447 for analytical methods. All rates are unadjusted.

HIGHEST RATES OF REPORTED INCIDENT ESRD, 2011 (PER MILLION POPULATION, UNADJUSTED; FIGURE 12.3) Jalisco (Mexico): 527 ; United States: 362; Taiwan (2010): 361

INCIDENT PATIENTS WITH ESRD DUE TO DIABETES, 2011 (PERCENT; FIGURE 12.4) Singapore: 61; Jalisco (Mexico): 60; Malaysia: 59

HIGHEST RATES OF REPORTED PREVALENT ESRD, 2011 (PER MILLION POPULATION, UNADJUSTED; FIGURE 12.6) Taiwan: 2,584; Japan: 2,309; United States: 1,924

prevalent rates of a functioning graft, 2011 (per million population, unadjusted; figure 12.8) Norway: 629; Portugal: 610; United States: 596; Netherlands: 577

TRANSPLANT RATES, 2011 (PER MILLION POPULATION, UNADJUSTED; FIGURE 12.9) Jalisco (Mexico): 62; Norway: 61; United States: 57; Iceland: 53; Spain: 53; Netherlands: 52; Portugal: 50



volume two



INTERNATIONAL COMPARISONS